Ampio Pharmaceuticals, Inc. (AMPE) |
|
3.67 -0.062 (-1.66%)
|
09-27 15:42 |
|
Open: |
3.68 |
Pre. Close: |
3.7321 |
|
High:
|
3.825 |
Low:
|
3.649 |
|
Volume:
|
9,817 |
Market Cap:
|
3(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 4:17:38 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 5.27 One year: 6.07 |
| Support: |
Support1: 3.4 Support2: 2.82 |
| Resistance: |
Resistance1: 4.51 Resistance2: 5.19 |
| Pivot: |
4.24 |
| Moving Average: |
MA(5): 3.9 MA(20): 4.17 
MA(100): 4.7 MA(250): 5.75 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 7.1 %D(3): 13.2 |
| RSI: |
RSI(14): 40.4 |
| 52-week: |
High: 21 Low: 3.4 |
| Average Vol(K): |
3-Month: 35 (K) 10-Days: 46 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AMPE ] has closed above bottom band by 10.2%. Bollinger Bands are 14.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.01 - 4.05 |
4.05 - 4.07 |
|
Low:
|
3.54 - 3.59 |
3.59 - 3.62 |
|
Close:
|
3.68 - 3.76 |
3.76 - 3.8 |
|
Company Description |
|
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado. |
Headline News |
Tue, 26 Sep 2023
Ampio Pharmaceuticals to Present at the Emerging Growth Conference - Yahoo Finance
Tue, 12 Sep 2023
Healthcare Stocks on the Move Tuesday: AMPE, AXLA, MYO, PIII, SGHT, OFIX, CGC, AYRWF - InvestorsObserver
Thu, 31 Aug 2023
Ampio Pharmaceuticals Announces Reverse Stock Split - Yahoo Finance
Thu, 22 Jun 2023
3 Biotech Stocks to Buy With Explosive Upside Potential - InvestorPlace
Fri, 26 May 2023
Ampio Pharmaceuticals Announces Series D Preferred Stock ... - PR Newswire
Tue, 18 Apr 2023
Ampio Pharmaceuticals Issues Letter to Stockholders - April 18, 2023 - BioSpace
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
